Mind Cure Announces Launch Of iSTRYM, A Mental Wellness Digital Therapeutics Tool

Mind Cure Health (CSE: MCUR) has launched a digital therapeutic tool which has been designed to provide near real-time data on patient care while enhancing access to psychedelic research, procedures and protocols in the realm of mental health. Labelled as iSTRYM, the new platform will look to bridge gaps that currently exist between clients, researchers and therapists.

iSTRYM is being described as a centralized management system for a number of functions, including psychedelic therapeutic research, procedural information, and the deployment of care. The platform has utilized technology to record vast uncategorized data, with its app component used by patients to record location, heart rate, weather, mood and other metrics of relevance after therapy sessions to assist in discovering insights across datasets, which will then be used to support better diagnoses from clinicians.

With a focus on psychedelic assisted therapy sessions, the tool will look to collect data that is typically lost between clients, researchers, and therapists. These uncategorized data points, such as listed above, will be collected as a means of enhancing the understanding of patient feedback. This optimization will then be used by the company to create what is referred to as a “converge of commonalities” among patients that utilize the program, enabling deeper insights as a whole to develop what is described as “personalized care at scale.”

“As a life sciences and digital therapeutics company, providing speed to market with novel psychedelic therapies through deeper data analytics is a strength we are developing with iSTRYM. Further, as we build out our database for mental wellness, both therapists and individuals will get mental wellness protocols for wellness optimization and support. iSTRYM exists to become the source that individuals turn to for science-backed, personalized mental health support at scale.”

kelsey Ramsden, President & CEO

Mind Cure Health last traded at $0.70 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

The Hidden Environmental Cost of Fertilizer | Robin Dow

Could Silver Stay This High? | Joaquín Marias – Argenta Silver

Can Historic Silver Data Turn Into a New Mine? | Rob Macdonald – Equity Metals

Recommended

First Majestic Drills 3.43 g/t Gold Over 24.4 Metres At Jerritt Canyon

Goliath Resources Secures 100% Ownership of Golddigger Property in BC’s Golden Triangle

Related News

Mind Cure Health Begins Manufacturing Synthetic Ibogaine

Mind Cure Health (CSE: MCUR) this morning announced that it has begun the first stage...

Wednesday, March 3, 2021, 08:03:53 AM

Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury

Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one...

Wednesday, February 17, 2021, 07:27:04 AM

Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss

Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended...

Wednesday, October 27, 2021, 10:41:00 AM

Mind Cure Receives Health Canada Approval For Sale Of Moonbeam Mushroom Products

Mind Cure Health (CSE: MCUR) has received the required authorizations from Health Canada for its...

Wednesday, September 23, 2020, 08:33:06 AM

Mind Cure Health Receives Ethics Approval For Psychedelic Integration Protocol Study

Mind Cure Health (CSE: MCUR) has seen its integration protocol research study receive unconditional ethics...

Tuesday, March 9, 2021, 08:43:32 AM